On Thursday, Target Corporation (NYSE:TGT)’s shares inclined 0.38% to $79.06.
Target Corporation declared the appointment of Anu Gupta to the role of senior vice president, operational excellence. In this role, which is new to Target, Gupta will lead a dedicated team in simplifying and optimizing processes across the business to assist the retailer become more agile in anticipating and meeting guests’ needs. She will report to John Mulligan starting October 12. Mulligan was recently elevated to the position of Target’s first chief operating officer.
Gupta brings more than 20 years of expertise in driving operational excellence, leveraging global operating models counting outsourcing, procurement, lean six sigma process redesign and corporate development across diverse industries, counting retail. She formerly served as vice president for process and profit improvement at Michaels Stores, Inc., where she led the improvement of a variety of core business processes counting inventory productivity, product delivery lead times and store operations. Before Michaels, Gupta held an operational leadership role at Safeway, Inc. and was responsible for creating planned retail services initiatives. She joins Target from private equity investment firm Hellman & Friedman, where she was senior operating executive with oversight for improving business processes and productivity across its portfolio companies.
Gupta’s appointment comes as Target’s leadership renews its focus on improving operational fundamentals, particularly technology systems and platforms, supply chain and out-of-stocks and the guest experience. The retailer is investing a formerly declared $1 billion in supply chain and technology infrastructure this year, and is putting the right teams and leaders in place to spearhead the effort.
Target Corporation (Target) is engaged in providing everyday essentials and fashionable, and differentiated merchandise at discounted prices. The Company operates in two segments: U.S. and Canadian. The U.S. Segment includes all of its the United States retail operations, including digital sales.
Seagate Technology PLC (NASDAQ:STX)’s shares gained 1.26% to $44.10.
Reduxio Systems (Reduxio) won the Best of Show award in the Virtualization and Cloud Infrastructure category at VMworld 2015. Reduxio was recognized for its new HX550 Flash Hybrid storage system that eliminates the complexity that is associated with managing storage systems and its introduction of BackDating™ — a technology that obsoletes snapshots and simplifies the recovery of applications and data.
Unlike snapshots, which only provide infrequent discrete recovery points that have to be planned and configured upfront, BackDating works like a continuous data recorder — it lets an administrator clone or restore a volume to any point in time in the history of the system. This, combined with the flash-first architecture, enabled by the Tier-X™ tiering engine and the NoDup™ inline global dedupe and compression, makes the HX550 the most cost effective flash storage solution for enterprise applications.
Reduxio is backed by Seagate Technology PLC (NASDAQ: STX), a world leader in storage solutions, Jerusalem Venture Partners (JVP), Carmel Ventures and Intel Capital. Reduxio has secured $15 million in Series B and $12 million in Series A funding.
Seagate Technology plc (Seagate) is a provider of electronic data storage products. The Company’s products are hard disk drives (HDD). The Company produces a range of electronic data storage products, including solid state hybrid drives (SSHD), solid state drives (SSD), peripheral component interconnect express (PCIe) cards and Serial AT Attachment (SATA) controllers.
At the end of Thursday’s trade, Biogen Inc (NASDAQ:BIIB)‘s shares dipped -1.79% to $293.01.
Biogen and Swedish Orphan Biovitrum AB (publ) (Sobi) (SOBI.ST) received a positive recommendation from the European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of Elocta(TM) (rFVIIIFc). Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of haemophilia A that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the European Union (EU).
The positive opinion was based on results from the pivotal, phase 3 A-LONG clinical study, which examined the efficacy, safety and pharmacokinetics of rFVIIIFc in formerly treated males 12 years of age and older with severe haemophilia A, and from the phase 3 Kids A-LONG clinical study, which evaluated the efficacy and safety of rFVIIIFc in formerly treated male children with haemophilia A under 12 years of age. The Committee`s positive opinion is now referred to the European Commission (EC), which grants marketing authorization for medicines in the EU.
Elocta is the European trade name for rFVIIIFc, which is also known as Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] in the U.S., Canada, Australia, New Zealand and Japan, where it is approved for the treatment of haemophilia A. Commonly stated adverse drug reactions (>/= 1% of subjects) in the clinical studies were arthralgia, malaise, myalgia, headache and rash. Development of Factor VIII neutralizing antibodies (inhibitors) may occur following administration of Elocta.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.
Barclays PLC (ADR) (NYSE:BCS), ended its Thursday’s trading session with 0.53% gain, and closed at $15.19.
Barclays Capital - Weak global growth, driven by weakness in emerging markets, especially in China, drove the Q3 market selloff, according to Barclays’ latest flagship quarterly research publication Global Outlook: Position for mediocre growth. With China deceleration unlikely to reverse any time soon, and developed market growth predictable to remain steady but not spectacular, investors should tilt their equities exposure toward a more neutral position, from the modest overweight position recommended in the last Global Outlook.
While the growth of advanced economies has been subpar by historical standards, the global consumer has been a source of strength in the US, Europe and Japan, with consumption assisted by tightening labor markets and weak inflation. Tighter labor markets in the US, the UK and Japan mean that central banks may be more cautious about further monetary policy accommodation, despite a subdued inflationary outlook driven by softer demand and excess capacity in China and continental Europe. Government bonds appear less attractive as a ‘safe haven’ than during earlier stages of the recovery.
Valuations in most broad asset classes seem fair, but not particularly attractive. Equity valuations were improved by the Q3 sell-off, but they are not priced at a compelling discount. Credit valuations have also improved as a result of a slower sell-off, and present opportunities as spreads have widened and underlying fundamentals remain strong.
Barclays PLC (Barclays) is a global financial services holding company. The Company operates in five business segments: Personal and Corporate Banking (PCB), Barclaycard, Africa Banking, Investment Bank and Head Office. Barclays Bank PLC is a wholly owned subsidiary of Barclays. The Personal and Corporate Banking (PCB) comprises personal banking, mortgages, wealth & investment management, and corporate banking.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
